T 1285/11 (Polymorphs/PFIZER) of 15.12.2011
- European Case Law Identifier
- ECLI:EP:BA:2011:T128511.20111215
- Date of decision
- 15 December 2011
- Case number
- T 1285/11
- Petition for review of
- -
- Application number
- 08806952.1
- IPC class
- A61K 31/435C07D 213/71
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Polymorphs of 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-mehtyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof and methods for making the same
- Applicant name
- Pfizer Products Inc.
- Opponent name
- -
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 113(1)European Patent Convention Art 82European Patent Convention R 103(1)(a)European Patent Convention R 137(5)European Patent Convention R 164(2)European Patent Convention R 44(1)European Patent Convention R 71(2)European Patent Convention R 86(4) 1973
- Keywords
- Admissibility of amendments under Rules 137(5) and 164(2) EPC (yes)
Substantial procedural violation (yes) - lack of essential reasoning prior to refusal
Reimbursement of the appeal fee (yes)
Remittal (yes) - Catchword
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division for further prosecution on the basis of claims 1 to 10 of the main (sole) request filed on 11 March 2010 with the request for entry into the European phase.
3. The request for reimbursement of the appeal fee is allowed.